Patent for J&J’s Remicade invalidated, cheaper version looms

A cheaper version of Johnson & Johnson's top-selling drug, the pricey rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled that a key patent …

The rest is here: 
Patent for J&J’s Remicade invalidated, cheaper version looms